Stockscreener 앱 받기
1.51
2.03%
0.03
시간 외 거래:
1.49
-0.02
-1.32%
Tiziana Life Sciences Ltd 주식(TLSA)의 최신 뉴스
Tiziana Life Sciences (TLSA) COO discloses Form 3 share and option holdings - Stock Titan
Tiziana Life Sciences advances foralumab program with full Phase 2 enrollment and encouraging expanded access data – ICYMI - Yahoo Finance
Tiziana Life Sciences (TLSA) Completes Patient Enrollment in Cli - GuruFocus
Tiziana completes enrollment for Phase 2 trial in progressive MS study - Proactive Investors
Why Is TLSA Stock Rising Today? - Stocktwits
Tiziana Life Sciences completes enrollment in Phase 2a multiple sclerosis trial - Yahoo Finance
Tiziana Fully Enrolls its Phase 2 Placebo Controlled Multiple Sclerosis Trial - The Manila Times
Phase 2a MS trial fully enrolled at Tiziana Life Sciences (NASDAQ: TLSA) - Stock Titan
Nasal antibody for multiple sclerosis fills Phase 2 trial, results late Q3 2026 - Stock Titan
Tiziana Life Sciences Shares Drop After Company Unveils Plan to Spin Out IL-6 Program - MSN
Tiziana Life Sciences (TLSA) Reports Positive Data on Foralumab for Multiple Sclerosis - GuruFocus
Updated Clinical Results for Tiziana Life Sciences (TLSA) Show P - GuruFocus
Tiziana Life Sciences price target boosted on foralumab update - Yahoo! Finance Canada
Market movers: Amer Sports, Tiziana Life Sciences, Ideal Power, NanoViricides... - Proactive financial news
Tiziana reports encouraging Expanded Access data for Foralumab in MS patients - Proactive financial news
Tiziana posts new data for multiple sclerosis drug (TLSA) - Seeking Alpha
Tiziana Announces New Positive Clinical Data for Intranasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis - BioSpace
Tiziana Life Sciences reports encouraging one-year data for intranasal foralumab in progressive MS - Proactive financial news
Intranasal foralumab shows SPMS safety and fatigue gains at Tiziana (Nasdaq: TLSA) - Stock Titan
User - FinancialContent
Tiziana Brain Trial Draws Fresh Nasdaq Index Attention - Kalkine Media
Tiziana Life Sciences (TLSA) Reports Positive Early Results in C - GuruFocus
Small cap wrap: VivoPower, BioHarvest Sciences, Phunware, Tiziana Life Sciences… - Proactive financial news
Tiziana Reports Reduced Brain Inflammation in Multiple System Atrophy Patients Treated with Intranasal Foralumab - Investing News Network
Tiziana Life Sciences (TLSA) Reports Positive Early Results in Clinical Trial - GuruFocus
Tiziana Life Sciences reports brain inflammation reductions in Multiple System Atrophy trial - Yahoo News Canada
Tiziana reports brain inflammation reduction in MSA trial patients By Investing.com - Investing.com Nigeria
Tiziana reports brain inflammation reduction in MSA trial patients - Investing.com UK
Tiziana Life Sciences Posts Early PET Data Showing Reduced Brain Inflammation in MSA Trial of Intranasal Foralumab - TipRanks
Tiziana Reports Reduced Brain Inflammation In Multiple System Atrophy Patients Treated With Intranasal Foralumab - Mena FN
Brain inflammation falls in Tiziana (Nasdaq: TLSA) MSA PET trial - Stock Titan
TradingKey - TradingKey
TLSA SEC FilingsTiziana Life Sciences Ltd Com 10-K, 10-Q, 8-K Forms - Stock Titan
Why Tiziana (TLSA) business model holds up in any market (Momentum Building) 2026-05-06Price Target - newser.com
Tiziana Life Sciences | 20-F: FY2025 Annual Report - Moomoo
Tiziana Life Sciences (TLSA) posts 2025 loss and faces going concern risk - Stock Titan
Tiziana Life Sciences Delays Annual 20-F Filing - TipRanks
Tiziana (TLSA) Stock: In-Depth Look (Mini Selloff) 2026-04-23Growth Investing - Newser
Wall Street Zen Downgrades Tiziana Life Sciences (NASDAQ:TLSA) to Sell - MarketBeat
Tiziana (TLSA) Stock Large Cap Focus (Hovering) 2026-04-16Most Discussed Stocks - Cổng thông tin điện tử Tỉnh Sơn La
Small cap wrap: 1911 Gold, Sona Nanotech, Tiziana Life Sciences, Gunnison Copper… - Proactive financial news
Tiziana Life Sciences (TLSA) Unveils Promising Preclinical Findi - GuruFocus
0.98%
0.12%
자본화:
|
볼륨(24시간):